Intrathecal Administration of Ziconotide as a Potential Treatment for Chronic Migraines

被引：4
作者：
Holden, Ryan [1 ]
Chauhan, Gaurav [2 ]
Emerick, Trent [3 ]
机构：
[1] Univ Pittsburgh, Med Ctr, Anesthesiol & Perioperat Med, Pittsburgh, PA USA
[2] Univ Pittsburgh, Med Ctr Presbyterian, Anesthesiol & Perioperat Med, Pittsburgh, PA 15260 USA
[3] Univ Pittsburgh, Med Ctr, Pain Med, Pittsburgh, PA USA
来源：
CUREUS JOURNAL OF MEDICAL SCIENCE | 2022年 / 14卷 / 03期
关键词：
intrathecal pump therapy; neuropathic pain treatment; chronic pain management; ziconotide; migraines; FACIAL-PAIN; MONOTHERAPY; EXPERIENCE; RESOLUTION;
D O I：
10.7759/cureus.23714
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Migraine is one of the most prevalent and debilitating illnesses globally. There are multitudes of treatment options available for migraines. One of the emerging treatment options for migraine, refractory to conventional treatment modalities, is the intrathecal Ziconotide. Ziconotide (Prialt, Jazz Pharmaceuticals, Dublin, Ireland) enforces selective block of N-type calcium channels, which control neurotransmission at many synapses. Ziconotide is proposed to have efficacy for chronic neuropathic pain, with a favorable lack of tolerance and chemical dependency. Few studies in the literature report the successful resolution of migraine headaches with Ziconotide. The authors report the successful use of intrathecal Ziconotide therapy for chronic refractory migraines.
引用
收藏
页数：6
相关论文
共 50 条
[41]   Intrathecal Ziconotide and Opioid Combination Therapy for Noncancer Pain: An Observational Study [J].
Deer, Timothy ;
Kim, Christopher ;
Bowman, Richard ;
Tolentino, Diana ;
Stewart, C. ;
Tolentino, Wilfrid .
PAIN PHYSICIAN, 2009, 12 (04) :E291-E296
[42]   Effect of First-Line Ziconotide Intrathecal Drug Therapy for Neuropathic Pain on Disability, Emotional Well-Being, and Pain Catastrophizing [J].
Shao, Miriam M. ;
Khazen, Olga ;
Hellman, Abigail ;
Czerwinski, Margaret ;
Dentinger, Rachel ;
DiMarzio, Marisa ;
Gillogly, Michael ;
Hadanny, Amir ;
Argoff, Charles ;
Pilitsis, Julie G. .
WORLD NEUROSURGERY, 2021, 145 :E340-E347
[43]   Delivery of ziconotide to cerebrospinal fluid via intranasal pathway for the treatment of chronic pain [J].
Manda, Prashanth ;
Kushwaha, Avadhesh Singh ;
Kundu, Santanu ;
Shivakumar, H. N. ;
Jo, Seong Bong ;
Murthy, S. Narasimha .
JOURNAL OF CONTROLLED RELEASE, 2016, 224 :69-76
[44]   What became of Prialt®? Observational study on the use of ziconotide in the treatment of chronic pain [J].
Loeschner, Denise ;
Dries, Rebecca ;
Kalff, Rolf ;
Walter, Jan ;
Reichart, Rupert .
SCHMERZ, 2021, 35 (05) :343-348
[45]   Use of Low Dose Ziconotide as First-Line Intrathecal Monotherapy [J].
Prusik, Julia ;
Argoff, Charles ;
Peng, Sophia ;
Pilitsis, Julie G. .
NEUROMODULATION, 2017, 20 (04) :386-391
[46]   In Vitro Stability of Low-Concentration Ziconotide Alone or in Admixtures in Intrathecal Pumps [J].
Dupoiron, Denis ;
Richard, Helene ;
Chabert-Desnot, Vincent ;
Devys, Catherine ;
Leynia, Pierre ;
Boisdron-Celle, Michele .
NEUROMODULATION, 2014, 17 (05) :472-482
[47]   Influence of pH and temperature on ziconotide stability in intrathecal analgesic admixtures in implantable pumps and syringes [J].
Bazin, Christophe ;
Poirier, Anne-Lise ;
Dupoiron, Denis .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2015, 487 (1-2) :285-291
[48]   An open-label, multicenter study of the safety and efficacy of intrathecal ziconotide for severe chronic pain when delivered via an external pump [J].
Donck, Ann Ver ;
Collins, Ronald ;
Rauck, Richard L. ;
Nitescu, Petre .
NEUROMODULATION, 2008, 11 (02) :103-111
[49]   The Relationship Between the Mechanisms of Action and Safety Profiles of Intrathecal Morphine and Ziconotide: A Review of the Literature [J].
Webster, Lynn R. .
PAIN MEDICINE, 2015, 16 (07) :1265-1277
[50]   Aseptic Arachnoiditis in a Patient Treated With Intrathecal Morphine Infusion: Symptom Resolution on Switch to Ziconotide [J].
Codipietro, Luigi ;
Maino, Paolo .
NEUROMODULATION, 2015, 18 (03) :217-220
12345